ZoomRx's Sagan Agents has been named a Finalist in the 2026 Fierce AI Innovation Awards, in the AI Innovation in Commercial Strategy & Launch category. The awards program, run by Questex's Fierce Life Sciences, recognizes organizations that are moving AI beyond pilots to deliver measurable impact across the life sciences and healthcare value chain from R&D and clinical trials to commercialization, manufacturing, and care delivery.
Sagan Agents was evaluated alongside entries from across the industry on five criteria: Innovation, Impact, Execution, Scalability, and Industry Relevance. Winners will be announced in the Fierce AI Innovation Report.
See the full list of 2026 finalists on Fierce's site
Sagan Agents is ZoomRx's AI operating system, purpose-built to agentify pharma customer insights and analytics workflows. Launched in May 2026, it is built on ZoomRx's data foundation - 15+ years of market context, 700M+ benchmark data points, and proprietary panel of 60,000+ HCPs and patients, and is designed to compress insights work that traditionally takes weeks into a continuous, AI-assisted loop.
"The platform has three components that work as one compounding system, each ending a different side of the trade-off pharma insights teams have always faced between speed, cost, and rigor:
Affordable - Data Archive Intelligence: the base platform layer that makes a team's entire research history (quant datasets, qualitative reports, claims, CRM) searchable and synthesizable by AI agents.
Fast - Agentic Market Research: end-to-end AI-powered survey design, fielding, analysis, and reporting, taking a research question to a strategy deck in days rather than weeks.
Rigorous - Strategic Insights Agents: purpose-built agents that accelerate insights workstreams such as segmentation, message testing, patient journey mapping, forecasting, brand health assessment, competitor tracking, and synthetic personas. Built on a composable skills framework: teams describe the workflow, and ZoomRx builds the agent."
Sagan Agents is built to extend insights professionals' judgment across every question the team runs, with every agent run transparent, auditable, and collaborative.
Earlier this year, a top-5 global biopharma firm ran a four-week AI hackathon to reimagine how its insights and analytics teams operate in an AI-first environment. Sagan Agents was selected to compete alongside some of the largest research and analytics vendors in the industry - validation that informed its submission for the Fierce AI Innovation Awards.
The AI Innovation in Commercial Strategy & Launch category recognizes AI applications that improve how life sciences companies plan and execute commercial and launch strategy. Sagan Agents was named alongside three other finalists in this category: AbbVie, DeepIntent, and Komodo Health, a category that reflects a broad mix of biopharma manufacturers and commercial AI/data platforms.
Being named a Finalist alongside established commercial-AI vendors signals that Sagan Agents' approach to agentic customer insights, combining a searchable research archive, purpose-built strategic insights agents, and end-to-end agentic market research is being recognized as a credible, differentiated model for how insights and analytics work is done in an AI-first pharma organization.
For brand teams, market research leads, and commercial strategy leaders evaluating AI tools for their own insights function, third-party recognition like this is one more data point when assessing which platforms are being validated by the industry.
Fierce AI Innovation Awards winners will be announced in the Fierce AI Innovation Report on September 2, 2026. ZoomRx will share the outcome across its channels when results are published.
Have questions about Sagan Agents or want to see it in action? Get in touch with the Sagan Agents team below.